Xu Zhang – InmunoES

Deciphering immune heterogeneity in lung adenocarcinoma via machine learning-based Differential Phenotype Immune Score: TPX2 as a key biomarker for immunotherapy resistance

27 de February de 2026 by Xu Zhang

BackgroundImmune heterogeneity is a major determinant of clinical outcome and immunotherapy responsiveness in lung adenocarcinoma (LUAD). However, the tumor-intrinsic transcriptional programs that drive immune divergence across patients remain insuffic…

Evaluation of ctDNA-guided adjuvant therapy de-escalation in head and neck squamous cell carcinoma: a comparative cohort study

7 de August de 2025 by Xu Zhang

BackgroundWhile circulating tumor DNA (ctDNA) assessment after surgery has emerged as a promising biomarker for minimal residual disease detection in solid tumors, its clinical utility for guiding the selection between postoperative radiotherapy (PORT)…

Unraveling the immune system’s role in peripheral nerve regeneration: a pathway to enhanced healing

21 de February de 2025 by Xu Zhang

Peripheral nerve injury (PNI) represents a common challenge in clinical practice. In contrast to the central nervous system (CNS), the peripheral nervous system (PNS) in mature mammals possesses a limited regenerative capacity. Upon the occurrence of P…